MetaCap

Harvard Bioscience Inc. (HBIO)

NASDAQ: HBIOIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD

8.66-0.02 (-0.23%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

HBIO stock chart

Technical analysis

Key statistics

All statistics
Market cap
$39.60M
EPS (TTM)
-$2.59
52-week range
4.00 – 10.20
Day range
8.53 – 9.00
Volume / Avg
22.66K / 21.82K
Beta
—

52-week range

$4.00$10.20

HBIO stock today

Harvard Bioscience (HBIO) closed at $8.66 on Nov 20, down 0.23% (-$0.02), versus the S&P 500's 3.70% decline. At this level, HBIO sits in the middle of its 52-week range of $4.00 to $10.20: 15.1% below the high, set on Nov 11, 2026 and 116.5% above the low. HBIO is up 29.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 37.5%.

Harvard Bioscience has posted a net loss over the last twelve months (EPS of -$2.59), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Harvard Bioscience

Company profile

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.

Industry
Biotechnology: Laboratory Analytical Instruments
CEO
Mr. John Duke
Headquarters
Holliston, MA
Employees
316
IPO year
2000

Financial highlights

Full financials

In fiscal 2025, Harvard Bioscience generated $86.5 million in revenue, down 8.1% from fiscal 2024, its first annual decline since 2024. Harvard Bioscience reported a net loss of $56.7 million, compared with a loss of $12.4 million a year earlier. Gross margin was 57.7% (down from 58.2%) and operating margin -56.1%.

Harvard Bioscience annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$86.55M$94.14M$112.25M$113.33M$118.90M
Growth-8.06%-16.14%-0.96%-4.68%+16.46%
Net income$-56.70M$-12.40M$-3.42M$-9.52M$-288.00K
EPS (diluted)$-1.28$-0.28$-0.08$-0.23$-0.01

Analyst forecast

Forecast

Consensus (2 analysts)

none

Avg. price target

$7.50-13.39%

  • Strong buy 1
  • Buy 0
  • Hold 1
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.10 vs $-0.65
Surprise
+84.62%

HBIO news

All HBIO news

Harvard Bioscience peers

Industrials sector
HBIO peer companies
CompanyPrice% ChgMarket capCompare
RPIDRapid Micro Biosystems Inc. Class A0.735-0.04%$37.37Mvs HBIO
PRPOPrecipio Inc.17.35-6.17%$31.11Mvs HBIO
EYPTEyePoint Inc.0.2342-11.36%$26.65Mvs HBIO
CIRCCircle8 Group Inc.0.1361-12.25%$15.99Mvs HBIO
BNGOBionano Genomics Inc.0.8222-7.11%$11.50Mvs HBIO
ASTCAstrotech Corporation (DE)3.50-0.85%$7.45Mvs HBIO
SEERSeer Inc. Class A1.36-1.81%$75.91Mvs HBIO
QTRXQuanterix Corporation1.96-3.45%$93.06Mvs HBIO

Indexes, lists and sector

Harvard Bioscience stock FAQ

What is Harvard Bioscience's stock price today?

HBIO last traded at $8.66 as of Nov 20, 4:00 PM EST, down 0.23% on the day. Prices are delayed at least 15 minutes.

Does Harvard Bioscience pay a dividend?

No. Harvard Bioscience does not currently pay a regular cash dividend.

Who is Harvard Bioscience's CEO?

Mr. John Duke is the chief executive officer of Harvard Bioscience Inc., which has about 316 employees.

Has HBIO ever split its stock?

Yes. The most recent HBIO stock split was a 1-for-10 split on Mar 16, 2026, one of 2 splits on record.

What is the HBIO 52-week high?

The 52-week high for HBIO is $10.20 and the 52-week low is $4.00. The stock is currently 15.1% below its high.

Compare HBIO